This morning PhRMA released a report, “Innovation in the Biopharmaceutical Pipeline: A Multi-Dimensional View”. The paper, by researchers at Analysis Group, examines the pipeline from several angles and helps to show the range of innovative research our companies are doing.
The reports find:
- More than 5,000 medicines are in development globally
- 70% of medicines in development are potentially first-in-class
- Personalized medicines and drugs for rare diseases are rapidly growing parts of the drug development pipeline
- Researchers are pursuing many new scientific approaches such as conjugated monoclonal antibodies and therapeutic cancer vaccines
Video streaming by Ustream
PhRMA’s reports are part of their ongoing efforts to communicate the important contributions PhRMA companies are making to save and improve lives.
Report: Analysis Group Report
Report: Accompanying PhRMA Report
Related Blog Posts
Examining the Biopharmaceutical Pipeline – Webinar Jan 14, 2013